- Home
- ARVN vs PNNT Comparison
ARVN vs PNNT Comparison
Compare ARVN & PNNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- PNNT
- Stock Information
- Founded
- ARVN 2015
- PNNT 2007
- Country
- ARVN United States
- PNNT United States
- Employees
- ARVN N/A
- PNNT N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- PNNT Finance: Consumer Services
- Sector
- ARVN Health Care
- PNNT Finance
- Exchange
- ARVN Nasdaq
- PNNT Nasdaq
- Market Cap
- ARVN 456.2M
- PNNT 442.7M
- IPO Year
- ARVN 2018
- PNNT 2007
- Fundamental
- Price
- ARVN $7.80
- PNNT $6.70
- Analyst Decision
- ARVN Buy
- PNNT Sell
- Analyst Count
- ARVN 21
- PNNT 3
- Target Price
- ARVN $20.53
- PNNT $5.88
- AVG Volume (30 Days)
- ARVN 2.2M
- PNNT 343.8K
- Earning Date
- ARVN 07-29-2025
- PNNT 08-06-2025
- Dividend Yield
- ARVN N/A
- PNNT 14.33%
- EPS Growth
- ARVN N/A
- PNNT N/A
- EPS
- ARVN N/A
- PNNT 0.73
- Revenue
- ARVN $426,900,000.00
- PNNT $138,371,000.00
- Revenue This Year
- ARVN $4.26
- PNNT N/A
- Revenue Next Year
- ARVN N/A
- PNNT N/A
- P/E Ratio
- ARVN N/A
- PNNT $9.18
- Revenue Growth
- ARVN 498.74
- PNNT N/A
- 52 Week Low
- ARVN $5.90
- PNNT $5.72
- 52 Week High
- ARVN $34.11
- PNNT $8.04
- Technical
- Relative Strength Index (RSI)
- ARVN 58.03
- PNNT 49.14
- Support Level
- ARVN $7.09
- PNNT $6.59
- Resistance Level
- ARVN $7.85
- PNNT $6.78
- Average True Range (ATR)
- ARVN 0.40
- PNNT 0.12
- MACD
- ARVN 0.06
- PNNT -0.02
- Stochastic Oscillator
- ARVN 71.43
- PNNT 29.00
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About PNNT PennantPark Investment Corporation
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.